Cerovive----?overdone enthusiasm
I read the PR and had trouble guessing whether the stock (RNVS) would go up or down today. My gut sense is that a doubling in share price on this news is overdone.
Biowatch, I don't think either of those two stroke assesment scales is widely used in clinical practice on individual patients. Rather, they are used for studies on aggregated patients.
This additional info from the PR gives a partial answer to your question:
Modified Rankin Scale (MRS): the most commonly used global disability
scale for assessing stroke patients. It is a simple measure of
independence primarily used in the rehabilitation phases of stroke.
* National Institute of Health Stroke Scale (NIHSS): provides a
quantitative assessment of the neurological examination findings that
are most relevant to stroke patients. This scale assesses neurological
impairment, providing a measure of the severity of the stroke and was
developed specifically for use in acute stroke trials.
So, my take is that the Rankin Scale likely reflects real-life functional status, but is more subjective and less reproducible. The NIHSS seems to be a tool devised for studying strokes. I don't know how well either is validated, but strongly suspect that even the honchos don't know because they allowed both scales to be primary endpoints.
Even though I was considering a buy, today I am considering a small short sale if it goes >$14. The news today seems ambiguous and the stock overheated.
My thoughts ,FWIW,but other opinions, please.
urche
Market Data 
Markets 
AI
